DR-176 Responder study, Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment.
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-176 Responder study, Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment.
Immune checkpoint inhibitors have been approved for first- and second-line treatment of metastatic urothelial cancer (mUC) patients, and lead to …
DR-174 Effects of FHIT gene in cancers
We aim to understand the effects of the FHIT gene in cancers. FHIT is involved in purine metabolism, and contains …
DR-173 Detection of microsatellite instability in metastatic colorectal cancer: the diagnostic accuracy of routine mismatch repair or microsatellite testing compared to whole genome sequencing.
The prognosis of patients with metastatic colorectal cancer is poor. Some of these patients are eligible for receiving potentially life-saving …
DR-172 Detecting RET gene fusions in lung cancer: multicenter experience and comparison of molecular testing modalities
RET fusion gene testing will soon become very important for selection of lung cancer patients for treatment with the novel …
DR-170 Combining somatic alterations in intergenic, intronic and exonic regions to improve tumor mutational burden estimation by targeted sequencing.
Purpose: To develop an algorithm for robust estimation of the tumor mutational burden (TMB) using targeted sequencing. Data: Somatic analyses …
DR-169 Assessing drug response in breast cancer tissue samples
Breast cancer (BC) is the most common malignancy among women, constituting the prominent cause of cancer-associated mortality. Despite considerable knowledge …
DR-165 Dynamical modelling of somatic genomes: structural variation and tumour evolution
Cancer cells can have very high mutation rates, an effect known as genetic instability. This creates high levels of structural …
DR-164 Functional annotation of the mutated regulatory landscape in glioblastoma
Glioblastoma multiforme (GBM) is the most lethal brain tumour. Mutations in certain genes have been implicated in GBM. However, the …
DR-163 Molecular archaeology of cancer metastases
We aim to apply computational tools to Hartwig Medical Foundation cancer genomes to establish the order in which harmful mutations …
DR-162 Genomic and transcriptomic analysis of e-cadherin mutated breast cancer
There are different types of breast cancer, one is referred to as Invasive Lobular Carcinoma (ILC). ILC accounts for around …
DR-160 Predicting the target-landscape of kinase-inhibitors with explainable 3D convolutional neural networks enables selection of highly personalized therapies
Many tumors show mutations of kinase proteins. When these kinase proteins are mutated, they can provide a catastrophic effect because …
DR-159 “Genomic characterization of metastatic urothelial carcinoma. DR-159 is an extension of DR-031”
See also HMF-DR-031 as this study will be part of DR-031.This project aims to assess the porportion of patients with …
Een complete DNA-test biedt bij patiënten met PTO de extra mogelijkheid om erachter te komen waar de kanker is begonnen. Hierdoor wordt vaak de primaire tumor toch gevonden. Daarnaast geeft de test vaak aanknopingspunten voor een gerichte behandeling.